Home > Insider Trading > Filing (0001387131-22-012411)

Filing Details

Accession Number:: 0001387131-22-012411
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-12-14 17:01:26
Reporting Period:: 2022-12-12

Accepted Time:: 2022-12-14 17:01:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1723128	Amneal Pharmaceuticals Inc.	AMRX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
860866	David Bonderman	C/O Tpg Inc. 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	No	Yes
1099776	G James Coulter	C/O Tpg Inc. 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	No	Yes
1366946	Jon Winkelried	C/O Tpg Inc. 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	No	Yes
1903793	Tpg Gp A, Llc	C/O Tpg Inc. 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Disposition	2022-12-12	3,884,600	$2.34	12,328,767	No	4	S	Indirect	See Explanation of Responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Explanation of Responses

Footnotes

Each of David Bonderman, James G. Coulter and Jon Winkelried own entities that own TPG GP A, LLC (together with Messrs. Bonderman, Coulter and Winkelried, the "Reporting Persons"), which is the managing member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc., which is the controlling shareholder of TPG GPCo, LLC, which is the managing member of each of (i) TPG Holdings I-A, LLC and (ii) TPG Holdings III-A, LLC. TPG Holdings I-A, LLC is the general partner of TPG Operating Group I, L.P., which is the sole member of TPG GenPar VII Advisors, LLC, which is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Improv Holdings, L.P., which directly holds 12,328,767 shares of Class A common stock ("Class A Shares") of Amneal Pharmaceuticals, Inc. (the "Issuer").
TPG Holdings III-A, LLC is the general partner of TPG Holdings III-A, L.P., which is the general partner of TPG Operating Group III, L.P., which is general partner of TPG PEP GenPar Advisors, L.P., which is the general partner of TPG PEP GenPar Governance, L.P., which is the general partner of each of (i) TPG Public Equity Partners, LP, which directly held Class A Shares, and (ii) TPG Public Equity Partners Master Fund, L.P. (together with TPG Improv Holdings, L.P. and TPG Public Equity Partners, LP, the "TPG Funds"), which directly held Class A Shares.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.34 to $2.465, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of the TPG Fund's or such Reporting Person's pecuniary interest therein, if any.
Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.